Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Concurrent β-blocker use improves survival in oesophageal cancer patients on chemoradiation

14 Dec 2020

Use of β-blockers results in significant survival benefits in oesophageal cancer patients receiving concurrent chemoradiation, a study has shown.

β-blockers have been associated with improved outcomes in several malignancies, but the impact of β-blockade in oesophageal cancer has not been well characterized. To address this, the authors analysed the charts of all 418 patients treated with radiation for oesophageal cancer at an institution from April 2010 to October 2018.

Those who underwent treatment with palliative intent or did not finish therapy were excluded in the analysis. The authors determined β-blocker use from the medication list at the time of pretreatment consultation.

A total of 291 patients with oesophageal cancer received neoadjuvant/definitive chemoradiation therapy, with a median follow-up of 22.5 months (interquartile range, 9.6–41.0 mo). Of these, 81 (27.8 percent) were on β-blockers at the time of treatment. Patients receiving β-blockers had significantly improved distant control (22.2 percent vs 37.9 percent; p=0.035).

Cox regression analysis revealed that concurrent β-blocker use significantly correlated with improved progression-free survival (hazard ratio [HR], 0.41, 95 percent confidence interval [CI], 0.27–0.66; p<0.001) and overall survival (HR, 0.55, 95 percent CI, 0.38–0.81; p=0.002).

In addition, propensity score-matched pairs were created using tumour stage, nodal stage, sex, neoadjuvant versus definitive therapy, Karnofsky Performance Status, and aspirin use. In this analysis, significant progression-free survival benefit was observed in oesophageal cancer patients receiving β-blockers (p=0.005).

“Concurrent β-blocker use is common within patients receiving concurrent chemoradiation for oesophageal cancer,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.